Study Details

Open

Polatuzumab vedotin with R-GDP in relapsed/refractory diffuse large B-cell lymphoma

The purpose of this study is to look at the effectiveness of a combination of treatments, polatuzumab vedotin with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP) at treating relapsed or refractory diffuse large B-cell lymphoma.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

During your participation, you will complete assessments including blood tests and scans to check on your cancer. These tests and assessments will be used to evaluate your response to the treatment you are receiving. If you become eligible for a stem cell transplant during the treatment, you will stop taking the study treatment and proceed to the transplant. Your eligibility for a transplant will be checked every 2 cycles. After completing treatment, the study team will follow up with you to see how you are doing after you stop taking study drugs.

Incentives

You or your insurance provider will not have to pay for the polatuzumab vedotin while you take part in this study

In-person visits:
14

Total length of participation:
4 months of treatment and 5 years of follow-up visits

Looking for Specific Volunteers

Able to participate:

You have been diagnosed with diffuse large B-cell lymphoma, and have received at least done previous round of therapy
You are over 18 years old

Not eligible if:

You have been diagosed with cardiac disease including ventricular dysfunction, left ventricular ejection fraction of less than 40%, sympomatic coronary artery disease or symptomatic arrhythmias
You have severely impaired liver function
Your disease has central nervous system involvement
You have a high amount of hearing loss, or were born with impaired or loss of hearing
You are taking prohibited medication of treatments, such as strong CYP3A inhibitors and inducers that cannot be replaced by an alternative therapy

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Christopher Dittus
Lineberger Comprehensive Cancer Center

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Lymphoma)

IRB Number

22-1663

ClinicalTrials.gov

NCT05498220